Skip to content
lifestyle.gopreneurs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NMD Pharma
SYNAPSE-CMT Phase 2a Clinical Study Data Presented in Late-Breaking Oral Presentation at 2026 PNS Annual Meeting
June 17, 2026
NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2
March 10, 2026
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 13, 2026
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
February 3, 2026